Cinomac HS Injection 1 ml

Cinomac HS Injection 1 ml belongs to the group of medicines called oxytocic agents indicated for the prevention of uterine atony and postpartum haemorrhage following cesarean section under epidural or spinal anaesthesia. Postpartum haemorrhage is a condition in which excessive bleeding occurs following childbirth

Cinomac HS Injection 1 ml contains Carbetocin, which is similar to oxytocin, which is naturally produced by the body and helps the womb contract during childbirth. Cinomac HS Injection 1 ml makes the womb contact and reduces the risk of bleeding.

In some cases, Cinomac HS Injection 1 ml may cause abdominal pain, dizziness, feeling of warmth, headache, nausea, and vomiting. Most of these side effects may not require medical attention and resolve gradually over time. However, if the side effects persist or worsen, consult a doctor.

Do not receive Cinomac HS Injection 1 ml if you are pregnant. Consult the doctor if you are breastfeeding. Cinomac HS Injection 1 ml is not recommended for children as safety and effectiveness have not been established. Keep your doctor informed about your health condition and medications to rule out any interactions/side effects.

Cinomac HS Injection 1 ml is used in the treatment of Postpartum haemorrhage and uterine atony. The detailed uses of Cinomac HS Injection 1 ml are as follows:

• Prevent postpartum hemorrhage: Cinomac HS Injection 1 ml promotes strong and sustained uterine contractions immediately after childbirth, reducing the risk of excessive bleeding due to uterine atony.
• Support cesarean section recovery: Cinomac HS Injection 1 ml is administered after elective cesarean delivery under spinal or epidural anaesthesia to stabilize uterine tone and minimize blood loss.
• Mimic oxytocin activity: Cinomac HS Injection 1 ml acts as a long-acting oxytocin receptor agonist, binding to receptors in the uterine muscle to increase contraction frequency and intensity.

• Follow your doctor’s instructions on the dosage and timing of this medication, to improve effectiveness.
• Cinomac HS Injection 1 ml will be administered by a healthcare professional.
• Do not self-administer it.

Cinomac HS Injection 1 ml belongs to the group of medicines called oxytocic agents indicated for the prevention of uterine atony and postpartum haemorrhage following cesarean section under epidural or spinal anaesthesia. Cinomac HS Injection 1 ml contains Carbetocin, which is similar to oxytocin, which is naturally produced by the body and helps the womb contract during childbirth. Cinomac HS Injection 1 ml makes the womb contact and reduces the risk of bleeding.

Cinomac HS Injection 1 ml should not be used if you are allergic to any of its components, during pregnancy and labour before delivery of the infant, or for the induction of labour. Inform the doctor if you have serious heart disorders, epilepsy, high blood pressure, blood clotting problems, gestational diabetes, migraine, asthma, or liver/kidney impairment. Consult the doctor if you are breastfeeding. The safety and effectiveness of Cinomac HS Injection 1 ml in children have not been established. Let your doctor know if you are taking any prescription/non-prescription medicines, including herbal products and supplements.